Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 5 versus THYROLAR 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 5 versus THYROLAR 3.
THYROLAR-0.5 vs THYROLAR-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone replacement; L-thyroxine (T4) is converted to active triiodothyronine (T3) which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate and oxygen consumption.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
Initial dose 0.5 tablets (30 mg T4/7.5 mg T3) orally once daily, titrated every 2-4 weeks based on TSH, free T4, and free T3 levels; usual maintenance 0.5-2 tablets (30-120 mg T4/7.5-30 mg T3) once daily.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
None Documented
None Documented
For liothyronine (T3): approximately 1.5-2.5 days; for levothyroxine (T4): approximately 6-7 days. In hyperthyroidism, half-life may be shortened; in hypothyroidism, prolonged.
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Renal (approximately 40-50% as unchanged drug and conjugates), fecal (approximately 20-30% via biliary elimination), with the remainder metabolized and eliminated via urine and feces.
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone